Vivos has reached an agreement with GM Instruments to better measure nasal breathing in sleep apnea treatment and research.
Vivos Therapeutics has announced an exclusive distribution agreement with GM Instruments for the distribution of GM Instruments’ NR6 Rhinomanometer. This is the only Food and Drug Administration (FDA) approved 4-phase rhinomanometer available in the United States. It’s used to calculate nasal airway resistance through measuring nasal flow and the pressure producing that flow.
Vivos will become the exclusive North American distributor of this specialized diagnostic equipment through this agreement. This aligns with Vivos’s mission which is focused on creating treatment for patients that deal with mild to moderate obstructive sleep apnea (OSA) and snoring.
With the ability to measure nasal breathing, Vivos will be better able to determine best breathing and sleep issue treatment pathway and CPAP intolerance/treatment failure, according to Vivos Chairman and CEO, Kirk Huntsman.
“With this new agreement, every U.S. or Canadian dentist who wishes to evaluate the breathing function of a patient will need to engage with Vivos for this diagnostic equipment,” Hunstman said in a press release from the company. “We expect this will provide Vivos an immediate new revenue stream as well as a substantial competitive advantage and opportunity to present Vivos’ proprietary oral appliance technology to a wider audience.”
The NR6 Rhinomanometer from GM Instruments is designed to be a quick test to measure nose function during breathing, and the test results can now be used by Vivos-trained dentists to keep track of pre-, mid-, and post-treatment of patients. Because breathing and flow are so vital to treatment of OSA and snoring, this agreement can be a huge boon according to Vice President of Sales for GM-Instruments, North America, Karen Parker Davidson, RN.
“Many medical problems such as OSA, overall lung function, and even spinal and posture issues are related to nasal resistance and poor breathing, and our breathing is disrupted before our sleep is disrupted,” Dr Parker Davidson said in the press release. “With this strong collaboration with Vivos, we believe we have the opportunity to change the standard of care for OSA to improve patient outcomes and manage their health with better testing and assessments.”